224 related articles for article (PubMed ID: 38170178)
41. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
42. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
Cortes JR; Patrone CC; Quinn SA; Gu Y; Sanchez-Martin M; Mackey A; Cooke AJ; Shih BB; Laurent AP; Trager MH; Ferrando AA; Geskin LJ; Palomero T
J Invest Dermatol; 2021 Dec; 141(12):2908-2920.e7. PubMed ID: 34089720
[TBL] [Abstract][Full Text] [Related]
43. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
44. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
45. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
Reddy SA
Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
[TBL] [Abstract][Full Text] [Related]
46. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
[TBL] [Abstract][Full Text] [Related]
47. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
Nguyen CN; Iyer SP; Duvic M; Barde PJ; Nair A; Routhu KV; Huen AO
Invest New Drugs; 2023 Apr; 41(2):350-355. PubMed ID: 37004644
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma.
Stephen S; Morrissey KA; Benoit BM; Kim EJ; Vittorio CC; Nasta SD; Showe LC; Wysocka M; Rook AH
Am J Hematol; 2012 Feb; 87(2):226-8. PubMed ID: 22189940
[TBL] [Abstract][Full Text] [Related]
49. T lymphocyte activation by staphylococcal enterotoxins: role of class II molecules and T cell surface structures.
Fleischer B; Schrezenmeier H; Conradt P
Cell Immunol; 1989 Apr; 120(1):92-101. PubMed ID: 2522832
[TBL] [Abstract][Full Text] [Related]
50. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
51. Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor.
Dohlsten M; Hedlund G; Segren S; Lando PA; Herrmann T; Kelly AP; Kalland T
Eur J Immunol; 1991 May; 21(5):1229-33. PubMed ID: 1645269
[TBL] [Abstract][Full Text] [Related]
52. Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients.
Emge DA; Bassett RL; Duvic M; Huen AO
Arch Dermatol Res; 2020 May; 312(4):283-288. PubMed ID: 31776647
[TBL] [Abstract][Full Text] [Related]
53. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
54. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.
Kelly-Sell MJ; Kim YH; Straus S; Benoit B; Harrison C; Sutherland K; Armstrong R; Weng WK; Showe LC; Wysocka M; Rook AH
Am J Hematol; 2012 Apr; 87(4):354-60. PubMed ID: 22367792
[TBL] [Abstract][Full Text] [Related]
55. Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for molecular-specific treatment.
Rendón-Serna N; Correa-Londoño LA; Velásquez-Lopera MM; Bermudez-Muñoz M
Int J Dermatol; 2021 Dec; 60(12):1462-1480. PubMed ID: 33835479
[TBL] [Abstract][Full Text] [Related]
56. Staphylococcus aureus and Sézary syndrome.
Merlio JP
Blood; 2024 Apr; 143(15):1436-1438. PubMed ID: 38602696
[No Abstract] [Full Text] [Related]
57. Transcriptional Heterogeneity and the Microbiome of Cutaneous T-Cell Lymphoma.
Licht P; Mailänder V
Cells; 2022 Jan; 11(3):. PubMed ID: 35159138
[TBL] [Abstract][Full Text] [Related]
58. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma.
Kamstrup MR; Gjerdrum LM; Biskup E; Lauenborg BT; Ralfkiaer E; Woetmann A; Ødum N; Gniadecki R
Blood; 2010 Oct; 116(14):2504-12. PubMed ID: 20538790
[TBL] [Abstract][Full Text] [Related]
59. Staphylococcal enterotoxin-dependent lysis of MHC class II negative target cells by cytolytic T lymphocytes.
Herrmann T; Romero P; Sartoris S; Paiola F; Accolla RS; Maryanski JL; MacDonald HR
J Immunol; 1991 Apr; 146(8):2504-12. PubMed ID: 1707909
[TBL] [Abstract][Full Text] [Related]
60. Staphylococcus aureus Isolated from Skin from Atopic-Dermatitis Patients Produces Staphylococcal Enterotoxin Y, Which Predominantly Induces T-Cell Receptor Vα-Specific Expansion of T Cells.
Aziz F; Hisatsune J; Yu L; Kajimura J; Sato'o Y; Ono HK; Masuda K; Yamaoka M; Salasia SIO; Nakane A; Ohge H; Kusunoki Y; Sugai M
Infect Immun; 2020 Jan; 88(2):. PubMed ID: 31740530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
